Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2017-06-04 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Cleansing Statement 1 page 110.9KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708AA(2)(f) of the Corporations Act 2001 regarding a fully underwritten non-renounceable pro-rata entitlement offer to raise approximately $7 million. It details the terms of the entitlement offer, the record date, issue price, and compliance with relevant sections of the Act. The document is short (2197 characters) and serves as an announcement of a capital raising event rather than a full financial report or detailed financing update. It does not contain financial statements or detailed analysis but is a formal notification to the ASX and shareholders about the capital raising. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2017-06-04 English
Appendix 3B 8 pages 163.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of securities issued, issue price, purpose of the issue, entitlement offer details, underwriting information, and application for quotation of additional securities on the ASX. It references ASX rules and compliance requirements related to new share issues. The content is focused on announcing and providing regulatory details about a capital raising event and the subsequent quotation of the new shares. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing unrelated to capital changes. Therefore, the correct classification is CAP with high confidence.
2017-06-04 English
Letter to Eligible Shareholders 3 pages 147.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 5 June 2017 from Cyclopharm Limited regarding a non-renounceable entitlement offer to raise approximately $7.0 million. It details the terms of the offer, issue price, eligible shareholders, additional new shares, capital structure pro-forma, and important dates related to the offer. The document does not contain financial statements or detailed financial analysis but rather provides information about a capital raising event and the process for shareholders to participate. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes. The document length is 5646 characters, which is sufficient to provide substantive details about the financing event, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is CAP with high confidence.
2017-06-04 English
Letter to Ineligible Shareholders 2 pages 155.9KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 5 June 2017 from Cyclopharm Limited informing certain shareholders that they are ineligible to participate in a non-renounceable pro-rata entitlement offer to raise approximately $7 million. It explains the eligibility criteria and states that the company will not be extending the offer to these shareholders. The document is a notification about a capital raising event, specifically an entitlement offer, and does not contain financial statements or detailed financial data. It is not a full report but an announcement related to financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 3804 characters, which is consistent with a letter or announcement rather than a full report.
2017-06-04 English
Response to ASX query on Appendix 3Y 4 pages 625.9KB
Director's Dealing Classification · 95% confidence The document is a letter from ASX Compliance to Cyclopharm Limited regarding a late lodgement of Appendix 3Y, which relates to changes in directors' interests in shares. It discusses compliance with ASX listing rules 3.19A and 3.19B about timely disclosure of directors' shareholdings. The document includes the company's response explaining the delay and the measures taken to ensure future compliance. This is a regulatory compliance correspondence about director shareholding disclosures, specifically about insider trading and director dealings. It is not a financial report, earnings release, or management discussion. It fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 6806 characters, containing detailed explanation and regulatory references, confirming it is not a brief announcement or a certification letter. Therefore, the classification is DIRS with high confidence.
2017-06-01 English
CYC - Positive Results of China Clinical Trial 2 pages 70.7KB
Capital/Financing Update Classification · 85% confidence The document is a company announcement from Cyclopharm Limited dated 1 June 2017, reporting positive results from a clinical trial in China regarding the use of Technegas in diagnosing COPD. It discusses trial results, ongoing and planned clinical trials, market potential, and strategic implications. The document is a detailed update on clinical trial outcomes and business strategy rather than a financial report or regulatory filing. It does not contain financial statements, audit information, or executive changes. It is not a transcript, nor a voting result or dividend notice. The content is primarily an operational and clinical update with market implications, fitting best under Capital/Financing Update (CAP) as it relates to clinical trial progress and potential market expansion, which impacts company valuation and capital strategy. The document length (6052 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2017-05-31 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.